Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Consensus Target Price of $18.75 According to Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $18.75.

A number of research analysts recently weighed in on the stock. Weiss Ratings raised shares of Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday.

View Our Latest Report on Kalaris Therapeutics

Kalaris Therapeutics Stock Down 7.3%

KLRS opened at $1.46 on Friday. The firm’s fifty day moving average price is $2.49 and its two-hundred day moving average price is $5.02. Kalaris Therapeutics has a 1 year low of $1.41 and a 1 year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06. Sell-side analysts predict that Kalaris Therapeutics will post -1.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Kalaris Therapeutics

Hedge funds have recently modified their holdings of the company. Sigma Planning Corp purchased a new position in shares of Kalaris Therapeutics in the 2nd quarter worth approximately $41,000. Empowered Funds LLC bought a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $65,000. WealthTrust Asset Management LLC bought a new position in shares of Kalaris Therapeutics in the first quarter valued at approximately $72,000. Velan Capital Investment Management LP grew its holdings in shares of Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Kalaris Therapeutics by 146.8% during the third quarter. Goldman Sachs Group Inc. now owns 39,616 shares of the company’s stock valued at $114,000 after acquiring an additional 23,562 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

(Get Free Report)

Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.

Recommended Stories

Analyst Recommendations for Kalaris Therapeutics (NASDAQ:KLRS)

Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.